摘要
目的:观察艾迪注射液联合化疗治疗恶性淋巴瘤对免疫功能的影响。方法:将60例患者随机分成治疗组与对照组,每组各30例。两组均采用CHOP方案化疗,21 d为1周期。治疗组加用艾迪注射液治疗,15 d为1疗程,2疗程后评价疗效。观察两组治疗后生活质量、免疫功能及不良反应变化情况。结果:两组治疗后生活质量比较,治疗组与对照组升高稳定率分别为83.3%、60.0%,差异有统计学意义(P<0.05)。两组治疗前后T淋巴细胞亚群比较,两组CD4+细胞、CD4+/CD8+比值均有明显下降,治疗组CD4+/CD8+比值与对照组比较,差异有统计学意义(P<0.05);治疗组治疗后CD8+明显增加,与治疗前比较,差异有统计学意义(P<0.05);与对照组比较,差异无统计学意义(P>0.05)。不良反应比较,治疗组明显低于对照组(P<0.05)。结论:艾迪注射液联合化疗恶性淋巴瘤能提高机体免疫功能、减轻不良反应、提高生活质量、延长生存期。
Objective： To observe the influence on immune function by Adie injection combined with chemotherapy m the treatment ot lymphadenoma. Methods ：60 cases were randomly divided into treatment group and control group ,30 cases of each group. Both group use chemotherapy with CHOP scheme,21 days as one cycle. The treatment group was added with Adie injection, 15 days as one cycle. Com-pare the life quality, immune function and adverse reaction of two groups before and after the treatment after two course of treatment. Re-suits：Compare the life quality in two groups after treatment. The rise stable rate of the treatment group and control group was 83.3% and 60.0% ,the difference was statistically significant（ P 〈 0.05 ）. Compare T lymphocyte subpopulations before and after treatment, CD4 and CD46＋/CD8^＋ ratio of the two groups were obviously declining. The difference was statistically significant（P 〈 0.05 ）. The CD8^＋ of treatment group is obviously increased compared with before, the difference was statistically significant （P 〈 0.05 ）. The difference was not statistically significant compared with control group（ P 〉 0.05 ）. Adverse reaction of the treatment group was significantly lower than the control group（P 〈 0. 05）. Conclusion：Adie injection combined with chemotherapy in the treatment of lymphadenoma can im-prove immune function, reduce adverse reactions, improve the quality of life and extend life span.
出处
《中医学报》
CAS
2012年第7期789-790,共2页
Acta Chinese Medicine
关键词
恶性淋巴瘤
艾迪注射液
化学疗法
免疫功能
瘰疬
石疽
恶核
lymphadenoma
Adie injection
chemotherapy
immune function
scrofula
hard nodule
lymphademectasis
